T. Helmberger (Munich, Germany)
Klinikum BogenhausenAuthor Of 1 Presentation
111P - Real-world outcomes of patients with breast cancer liver metastases treated with transarterial radioembolization: results from CIRT, a large European prospective multi-centre observational study
Abstract
Background
Transarterial radioembolization (TARE) is a treatment option for patients with primary and metastatic liver tumours. The CIRSE Registry for SIR-Spheres Therapy (CIRT, NCT02305459) was a European prospective multi-centre observational study designed to evaluate the clinical outcomes of patients treated with TARE for primary liver tumours and liver metastases from different organ origins, including breast cancer liver metastases (BCLM). The study was conducted by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Methods
Patients were enrolled prospectively between Jan 2015 and Dec 2017. Eligible patients were adults treated with TARE with Y90 resin microspheres for BCLM. Baseline characteristics and treatment-related data were collected with follow-up data every 3 months for 24 months including overall survival (OS), progression-free survival (PFS), hepatic progression-free survival (hPFS) and safety data.
Results
47 patients with BCLM were prospectively included from 13 sites in 6 European countries. Median age was 54 years (range 34-77) and 95.7% were female. Median time from liver metastatic diagnosis to TARE was 35.8 months and primary tumour was resected in 95.7% of the cases. 63.8% had extra-hepatic metastases (bone 31.9%, lymph nodes 4.3%, lung 2.1%, multiple locations 25.5%). All patients received TARE after at least one systemic therapy line: L1 10.6%, L2-5 51.0%, L≥6 36.1%. The investigator-assessed treatment intent of TARE was predominantly palliative (85.1%) or tumour downsizing (8.5%). After TARE, 42.6% of the patients received additional chemotherapy treatments. Median OS was 10.6 months (95% CI 7.3-14.4), median PFS 4.9 months (95% CI 3.2-7.0) and hPFS 6.0 months (95% CI 4.7-7.4). 40.4% of the patients experienced a total of 53 adverse events, with 7 (13.2%) being grade 3 or higher. 2 mild (grade 2) cases of radioembolization-induced liver disease were found.
Conclusions
Our data shows that in real-life, BCLM patients receive TARE late in their treatment pathway. In this predominantly palliative patient group, TARE can locally control tumours while displaying a low toxicity profile.
Clinical trial identification
NCT02305459, 2 December, 2014.
Legal entity responsible for the study
CIRSE - Cardiovascular and Interventional Radiological Society of Europe.
Funding
Sirtex Medical Europe.
Disclosure
D. Arnold: Advisory/Consultancy: Sirtex Medical Europe; Honoraria (self), Advisory/Consultancy: Terumo; Advisory/Consultancy: Boston Scientific; Advisory/Consultancy: Biocompatibles. All other authors have declared no conflicts of interest.